COPD Drug Delivery Devices Market (Product: Inhalers and Nebulizers; Type: Manual Devices and Digital Devices; and Distribution Channel: Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2030

Description

R&D and Product Innovation to Increase Adoption of COPD Drug Delivery Devices

The chronic obstructive pulmonary disease (COPD) drug delivery devices have garnered significant popularity in the past few decades, owing to consistent advancements in technology and development of innovative products. Inhaled medication has emerged as one of the most reliable and effective treatments for a broad range of respiratory diseases such as COPD and asthma. Within the COPD drug delivery devices market, focus on product innovation has gained significant momentum in the past 60 years - beginning from the advent of pressurized metered-dose inhalers. At present, although more than 230 devices and drug formulations are available, disease control continues to remain a major challenge.

Stakeholders operating in the current COPD drug delivery devices market are expected to focus on the development of innovative inhalers to improve the overall effectiveness of the inhaled medication therapy. Some of the innovations that are likely to take place within the COPD drug delivery devices market are expected to focus on digital technologies linked with inhalers, chemistry and formulations, and design and device engineering. Moreover, research and development activities are being undertaken to improve targeted drug delivery to the lungs. Furthermore, significant rise in the number of patients suffering from chronic obstructive pulmonary diseases worldwide coupled with a surge in demand for easy-to-operate devices is expected to drive the COPD drug delivery devices market to a value of US$ 11 Bn by 2027.

COPD Drug Delivery Devices Entering a Digital Era

In the current COPD drug delivery devices market landscape, digital drug delivery devices are garnering significant popularity. Trends suggest a gradual shift toward improved digital inhalation devices primarily used to treat patients suffering from respiratory diseases, including asthma and COPD. In recent times, focus on the development of novel drug delivery devices and systems has gained significant momentum in the pharmaceutical sector. In their bid to improve patient outcomes, stakeholders operating in the current market space are increasingly focusing on product development by adopting a patient-centric model.

Key players operating in the COPD drug delivery devices market are enhancing the designs of conventional drug delivery devices to improve patient outcomes. In terms of type, the digital devices segment is expected to grow at a CAGR of ~5% during the forecast period (2019-2027), a higher CAGR growth than the manual devices segment, which is poised to grow at a CAGR of 3.8% during the forecast period. Increase in the adoption of digital COPD drug delivery devices is expected to address the problems that conventional drug delivery techniques were incompetent in solving.

Companies Launch New Products to Stay Competitive in Global Market

Drug development pertaining to asthma has predominantly focused on new molecules in established classes, formulation of new devices, and a range of combination treatments. However, obtaining the approval of the FDA for these new COPD drug delivery devices is likely to remain a key for participants in the COPD drug delivery devices market landscape. In their efforts to establish a strong foothold in the market, several companies are launching new products with innovative designs and improved digital capabilities.

For instance, Lonza launched Capsugel ® Zephyr ™ - a new addition to the dry-powder inhalation capsule portfolio of the company. The company revealed that the launch of the new product was primarily aimed at fulfilling the growing demand for customized treatments for efficient COPD drug delivery.

While some stakeholders are adopting the strategy of product launches, others are actively engaged in seeking approval from the FDA. For instance, in December 2018, Teva announced that the FDA had approval its ProAir Digihaler COPD drug delivery device. The new device makes use of advanced sensors that can be connected to a mobile App, and is specifically developed for individuals suffering from COPD and asthma. The approval of this product is expected to provide an impetus for the adoption of digital technologies to develop cutting-edge COPD drug delivery devices. The COPD drug delivery devices market is a consolidated market with leading players, including Boehringer Ingelheim, GlaxoSmithKline plc, and AstraZeneca accounting for a collective market share of ~82% in 2018.

Analysts’  Viewpoint

The global COPD drug delivery devices market is expected to expand at a CAGR of 3.8% during the forecast period. This growth of the market can be attributed to the significant progress made in product development and integration of new digital technologies in the new-age COPD drug delivery devices. Stakeholders operating in the current market landscape should focus on gaining market share by acquiring small to mid-sized companies. North America and Europe will continue to remain the most prominent regions in the market, owing to favorable regulatory policies, focus on research and development, and growing investments toward product innovation and development. The COPD drug delivery devices in the Asia Pacific region is expected to witness the fastest CAGR growth  of ~5%, as awareness related to the benefits of digital COPD drug delivery devices will continue to grow.

COPD Drug Delivery Devices Market: Overview

COPD or chronic obstructive pulmonary disease is a progressive disorder that makes it difficult to breathe. Cigarette smoking is the leading cause of COPD. Moreover, long-term exposure to other lung irritants, such as air pollution, chemical fumes, or dust may also contribute to COPD development.

COPD drug delivery devices include inhaler and nebulizer, which effectively deliver the medication to the lungs and airways to treat or prevent diseases

COPD Drug Delivery Devices Market: Product Overview

Inhaled medication for COPD treatment is delivered through inhalers and nebulizers for effective results

Inhalers can be short-acting or long-acting. Long-acting bronchodilators include salmeterol, formoterol, vilanterol, and olodaterol. Bronchodilators include albuterol (Ventolin HFA), metaproterenol (Alupent), and levalbuterol (Xopenex). These drugs are administered through metered dose inhaler or dry powder inhaler to treat airflow obstruction caused by COPD.

Major types of inhalers include metered dose inhaler, dry powder inhaler, and soft mist inhaler. Nebulizers are sub-segmented into jet nebulizer, mesh nebulizer, and ultrasonic nebulizer.

The metered dose inhaler sub-segment dominated the inhaler segment. Growth of the sub-segment can be attributed to increase in demand for combination inhalers and promising drugs in pipeline.

COPD Drug Delivery Devices Market: Key Drivers

Increase in prevalence of COPD is a major cause that can be attributed to the growth of the global COPD drug delivery devices market. The disease burden is increasing among adults as well as in pediatric population, due to genetics or environmental factors, including microbial exposure, exposure to passive smoking, and air pollution, thereby increasing the need for COPD treatment. Increase in number of smokers is also fueling the COPD drug delivery devices market, as cigarette smoking (active or passive) is considered to be responsible for COPD.

Focus on spreading awareness about advantages of COPD treatment, including common treatment options such as pressurized meter dose inhalers and dry powder inhalers is also propelling the global COPD drug delivery devices market growth

Electronic monitoring devices for inhalers are significant applications of the digital technology for inhaled delivery systems. Rise in focus on smart or digital inhalers for administration of COPD drugs is driving the COPD drug delivery devices market growth.

Market Segmentation: COPD Drug Delivery Devices Market

Based on product, the global COPD drug delivery devices market has been divided into inhaler and nebulizer. Inhaler is further sub-segmented into metered dose inhaler, dry powder inhaler, and soft mist inhaler. Nebulizer is sub-segmented into jet nebulizer, mesh nebulizer, and ultrasonic nebulizer.

In terms of type, the global COPD drug delivery devices market has been bifurcated into manual device and digital device

Based on distribution channel, the global COPD drug delivery devices market has been classified into retail pharmacies, hospital pharmacies, and online pharmacies

Each of the segments has been analyzed in detail for market trends, recent trends & developments, drivers, restraints, opportunities, and useful insights. The report provides current and future revenue (US$ Mn) for each these segments for the period from 2017 to 2027, considering 2018 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2019 to 2027, along with market size estimations.

Regional Overview: COPD Drug Delivery Devices Market

In terms of region, the global COPD drug delivery devices market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been further divided into major countries and sub-regions.

The current and future market sizes in terms of revenue (US$ Mn) of these regional markets and their major countries have been provided in the report for the period from 2017 to 2027, with their CAGRs for the period from 2019 to 2027

The study also offers a list of recommendations, highlights, and useful insights of the market, which will help new companies willing to enter the market and existing companies to increase market shares, and help in the decision-making process

COPD Drug Delivery Devices Market: Major Players

The report concludes with the company profiles section that includes key information about the major players in the market

Leading players analyzed in the report are -

  • AstraZeneca
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc
  • Novartis AG
  • Teva Pharmaceutical Industries
  • Merck & Co., Inc.
  • Cipla Inc.
  • Sunovion Pharmaceuticals, Inc.
  • Koninklijke Philips N.V.
  • PARI GmbH
  • Omron Corporation

Each of these players has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments

Key Questions Answered in COPD Drug Delivery Devices Market Report

  1. What is the sales/revenue generated by COPD drug delivery devices market across all regions during the forecast period?
  2. What are the opportunities in the global COPD drug delivery devices market?
  3. What are the major drivers, restraints, opportunities, and threats in the global market?
  4. Which region is set to expand at the fastest CAGR during the forecast period?
  5. Which product segment is expected to generate the highest revenue globally in 2027? Which segment is projected expand at the highest CAGR during the forecast period?
  6. What are the market positions of different companies operating in the global market?

COPD Drug Delivery Devices Market - Segmentation

Product

  • Inhalers
  • Nebulizers

Type

  • Manual Devices
  • Digital Devices

Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

TABLE OF CONTENT

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global COPD Drug Delivery Devices Market

4. Market Overview

    4.1.  Introduction

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities 

    4.4. Global COPD Drug Delivery Devices Market Analysis and Forecast, 2017–2027

5. Key Insights

    5.1. Disease Prevalence in Key Countries

    5.2. Key Market Events 

    5.3. Regulatory Scenario

6. Global COPD Drug Delivery Devices Market Analysis and Forecasts, by Product

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Global COPD Drug Delivery Devices Market Value (US$ Mn) Forecast, by Product, 2017–2027

        6.3.1. Inhaler 

            6.3.1.1. Metered Dose Inhaler

            6.3.1.2. Dry Powder Inhaler

            6.3.1.3. Soft Mist Inhaler

        6.3.2. Nebulizer

            6.3.2.1. Jet Nebulizer

            6.3.2.2. Mesh Nebulizer

            6.3.2.3. Ultrasonic Nebulizer

    6.4. Global COPD Drug Delivery Devices Market Attractiveness, by Product

7. Global COPD Drug Delivery Devices Market Analysis and Forecasts, by Type

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Global COPD Drug Delivery Devices Market Value (US$) Forecast, by Type, 2017–2027

        7.3.1. Manual Device

        7.3.2. Digital Device

    7.4. Global COPD Drug Delivery Devices Market Attractiveness, by Type

8. Global COPD Drug Delivery Devices Market Analysis and Forecasts, by Distribution Channel

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Global COPD Drug Delivery Devices Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Online Pharmacies

    8.4. Global COPD Drug Delivery Devices Market Attractiveness, by Distribution Channel

9. Global COPD Drug Delivery Devices Market Analysis and Forecasts, by Region

    9.1. Key Findings

    9.2. Global COPD Drug Delivery Devices Market Value (US$ Mn) Forecast, by Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Global COPD Drug Delivery Devices Market Attractiveness, by Region

10. North America COPD Drug Delivery Devices Market Analysis and Forecast

    10.1. Introduction

    10.2. North America COPD Drug Delivery Devices Market Value (US$ Mn) Forecast, by Product, 2017–2027

        10.2.1. Inhaler 

            10.2.1.1. Metered Dose Inhaler

            10.2.1.2. Dry Powder Inhaler

            10.2.1.3. Soft Mist Inhaler

        10.2.2. Nebulizer

            10.2.2.1. Jet Nebulizer

            10.2.2.2. Mesh Nebulizer

            10.2.2.3. Ultrasonic Nebulizer

    10.3. North America COPD Drug Delivery Devices Market Value (US$ Mn) Forecast, by Type, 2017–2027

        10.3.1. Manual Device

        10.3.2. Digital Device

    10.4. North America COPD Drug Delivery Devices Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        10.4.1. Hospital Pharmacies

        10.4.2. Retail Pharmacies

        10.4.3. Online Pharmacies

    10.5. North America COPD Drug Delivery Devices Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        10.5.1. U.S.

        10.5.2. Canada

    10.6. North America COPD Drug Delivery Devices Market Attractiveness Analysis

        10.6.1. By Product

        10.6.2. By Type

        10.6.3. By Distribution Channel

        10.6.4. By Country 

11. Europe COPD Drug Delivery Devices Market Analysis and Forecast

    11.1. Introduction

    11.2. Europe COPD Drug Delivery Devices Market Value (US$ Mn) Forecast, by Product, 2017–2027

        11.2.1. Inhaler 

            11.2.1.1. Metered Dose Inhaler

            11.2.1.2. Dry Powder Inhaler

            11.2.1.3. Soft Mist Inhaler

        11.2.2. Nebulizer

            11.2.2.1. Jet Nebulizer

            11.2.2.2. Mesh Nebulizer

            11.2.2.3. Ultrasonic Nebulizer

    11.3. Europe COPD Drug Delivery Devices Market Value (US$ Mn) Forecast, by Type, 2017–2027

        11.3.1. Manual Device

        11.3.2. Digital Device

    11.4. Europe COPD Drug Delivery Devices Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        11.4.1. Hospital Pharmacies

        11.4.2. Retail Pharmacies

        11.4.3. Online Pharmacies

    11.5. Europe COPD Drug Delivery Devices Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Europe COPD Drug Delivery Devices Market Attractiveness Analysis

        11.6.1. By Product

        11.6.2. By Type

        11.6.3. By Distribution Channel

        11.6.4. By Country/Sub-region

12. Asia Pacific COPD Drug Delivery Devices Market Analysis and Forecast

    12.1. Introduction

    12.2. Asia Pacific COPD Drug Delivery Devices Market Value (US$ Mn) Forecast, by Product, 2017–2027

        12.2.1. Inhaler 

            12.2.1.1. Metered Dose Inhaler

            12.2.1.2. Dry Powder Inhaler

            12.2.1.3. Soft Mist Inhaler

        12.2.2. Nebulizer

            12.2.2.1. Jet Nebulizer

            12.2.2.2. Mesh Nebulizer

            12.2.2.3. Ultrasonic Nebulizer

    12.3. Asia Pacific COPD Drug Delivery Devices Market Value (US$ Mn) Forecast, by Type, 2017–2027

        12.3.1. Manual Device

        12.3.2. Digital Device

    12.4. Asia Pacific COPD Drug Delivery Devices Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        12.4.1. Hospital Pharmacies

        12.4.2. Retail Pharmacies

        12.4.3. Online Pharmacies

    12.5. Asia Pacific COPD Drug Delivery Devices Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Asia Pacific COPD Drug Delivery Devices Market Attractiveness Analysis

        12.6.1. By Product

        12.6.2. By Type

        12.6.3. By Distribution Channel

        12.6.4. By Country/Sub-region

13. Latin America COPD Drug Delivery Devices Market Analysis and Forecast

    13.1. Introduction

    13.2. Latin America COPD Drug Delivery Devices Market Value (US$ Mn) Forecast, by Product, 2017–2027

        13.2.1. Inhaler 

            13.2.1.1. Metered Dose Inhaler

            13.2.1.2. Dry Powder Inhaler

            13.2.1.3. Soft Mist Inhaler

        13.2.2. Nebulizer

            13.2.2.1. Jet Nebulizer

            13.2.2.2. Mesh Nebulizer

            13.2.2.3. Ultrasonic Nebulizer

    13.3. Latin America COPD Drug Delivery Devices Market Value (US$ Mn) Forecast, by Type, 2017–2027

        13.3.1. Manual Device

        13.3.2. Digital Device

    13.4. Latin America COPD Drug Delivery Devices Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        13.4.1. Hospital Pharmacies

        13.4.2. Retail Pharmacies

        13.4.3. Online Pharmacies

    13.5. Latin America COPD Drug Delivery Devices Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Latin America COPD Drug Delivery Devices Market Attractiveness Analysis

        13.6.1. By Product

        13.6.2. By Type

        13.6.3. By Distribution Channel

        13.6.4. By Country/Sub-region

14. Middle East & Africa COPD Drug Delivery Devices Market Analysis and Forecast

    14.1. Introduction

    14.2. Middle East & Africa COPD Drug Delivery Devices Market Value (US$ Mn) Forecast, by Product, 2017–2027

        14.2.1. Inhaler 

            14.2.1.1. Metered Dose Inhaler

            14.2.1.2. Dry Powder Inhaler

            14.2.1.3. Soft Mist Inhaler

        14.2.2. Nebulizer

            14.2.2.1. Jet Nebulizer

            14.2.2.2. Mesh Nebulizer

            14.2.2.3. Ultrasonic Nebulizer

    14.3. Middle East & Africa COPD Drug Delivery Devices Market Value (US$ Mn) Forecast, by Type, 2017–2027

        14.3.1. Manual Device

        14.3.2. Digital Device

    14.4. Middle East & Africa COPD Drug Delivery Devices Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027

        14.4.1. Hospital Pharmacies

        14.4.2. Retail Pharmacies

        14.4.3. Online Pharmacies

    14.5. Middle East & Africa COPD Drug Delivery Devices Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Israel

        14.5.4. Rest of Middle East & Africa

    14.6. Middle East & Africa COPD Drug Delivery Devices Market Attractiveness Analysis

        14.6.1. By Product

        14.6.2. By Type

        14.6.3. By Distribution Channel

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Competition Matrix

    15.2. Market Share Analysis, by Company (2018)

    15.3. Company Profiles

        15.3.1. AstraZeneca

            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.1.2. Company Financials

            15.3.1.3. Growth Strategies

            15.3.1.4. SWOT Analysis

        15.3.2. Boehringer Ingelheim GmbH

            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.2.2. Company Financials

            15.3.2.3. Growth Strategies

            15.3.2.4. SWOT Analysis

        15.3.3. GlaxoSmithKline plc

            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.3.2. Company Financials

            15.3.3.3. Growth Strategies

            15.3.3.4. SWOT Analysis

        15.3.4. Novartis AG

            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.4.2. Company Financials

            15.3.4.3. Growth Strategies

            15.3.4.4. SWOT Analysis

        15.3.5. Teva Pharmaceutical Industries

            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.5.2. Company Financials

            15.3.5.3. Growth Strategies

            15.3.5.4. SWOT Analysis

        15.3.6. Merck & Co., Inc.

            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.6.2. Company Financials

            15.3.6.3. Growth Strategies

            15.3.6.4. SWOT Analysis

        15.3.7. Cipla Inc.

            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.7.2. Company Financials

            15.3.7.3. Growth Strategies

            15.3.7.4. SWOT Analysis

        15.3.8. Sunovion Pharmaceuticals, Inc.

            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.8.2. Company Financials

            15.3.8.3. Growth Strategies

            15.3.8.4. SWOT Analysis

        15.3.9. Koninklijke Philips N.V.

            15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.9.2. Company Financials

            15.3.9.3. Growth Strategies

            15.3.9.4. SWOT Analysis

        15.3.10. PARI GmbH

            15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.10.2. Growth Strategies

            15.3.10.3. SWOT Analysis

        15.3.11. Omron Corporation

            15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.11.2. Company Financials

            15.3.11.3. Growth Strategies

            15.3.11.4. SWOT Analysis

Choose License Type

Checkout Inquiry Sample